Field Clinical Specialist
About the job
- Registered Nurse with current licensure.
- A minimum of 3–5 years of experience in cardiac surgery, cardiology, or critical care nursing.
- Demonstrated ability to develop and deliver clinical education programs for multidisciplinary audiences.
- Strong communication skills to translate complex clinical concepts for patients, families, and staff.
- Willingness to travel regularly to implanting center sites and flexibility for on-call clinical support.
- Provide specialized clinical nursing support for patients receiving mechanical circulatory support.
- Deliver patient and family education on device management, alarm response, and discharge protocols.
- Train nursing staff at implanting centers in mechanical circulatory support patient care competencies.
- Collaborate with clinical and engineering teams to develop and review patient management protocols.
- Participate in patient assessment and post-operative follow-up in conjunction with the medical team.
- Support the development of nursing-focused educational content for the learning management system platform.
- Prior exposure to mechanical circulatory support (VAD, ECMO, or TAH).
- Experience with learning management system platforms or digital learning content development.
About the company
BiVACOR is a clinical-stage medical device company developing the BiVACOR Total Artificial Heart (TAH) to replace a failing heart. The device is a compact, titanium implant that uses a single magnetically levitated rotor to pump blood to the lungs and the rest of the body, eliminating valves and mechanical bearings to reduce blood damage. It serves as a bridge-to-transplant and aims to become a long-term (permanent) alternative to heart transplantation. BiVACOR operates in the cardiovascular medtech space, pursuing regulatory approval through preclinical and clinical trials, including an FDA Breakthrough Device Designation and an Early Feasibility Study. Its strategy includes expanding from Australia to the US, securing funding, and advancing toward commercialization to address the large unmet need in end-stage heart failure.
Company Size
51-200
Company Stage
Grant
Total Funding
$46.7M
Headquarters
Huntington Beach, California
Founded
2008
Get referred to BiVACOR
See people who can refer or advise you
Simplify's Take
What believers are saying
- Five of five U.S. patients bridged to transplant by August 2025 without pump replacement.
- The 2026 clinical trial recruits four major centers: Duke, Banner, The Christ Hospital, Texas Heart.
- Australia’s MRFF and NIH grants fund wireless power development and clinical expansion.
What critics are saying
- The 15-patient expansion increases visibility; one stroke, hemolysis, or infection can halt approvals.
- Patients need anticoagulation, transplant eligibility, and chest fit; exclusions shrink the addressable pool.
- No commercial approval exists in 2026; late-stage trial failure would kill BiVACOR’s standalone thesis.
What makes BiVACOR unique
- BiVACOR’s single-maglev-rotor titanium TAH removes valves, bearings, and mechanical wear points.
- July 9, 2024 first-in-human implant and five-patient bridge-to-transplant run built credibility.
- FDA Breakthrough Device and TAP acceptance in 2025 signal unusually close regulator engagement.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- Health Savings Account/Flexible Spending Account
- Life Insurance
- Employee Assistance Program
- 401(k) Company Match
- Paid Vacation